Belite-Bio-Logo Digital-Full-Color.png
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
March 11, 2024 22:28 ET | Belite Bio, Inc
SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting...
Belite-Bio-Logo Digital-Full-Color.png
Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
March 11, 2024 21:27 ET | Belite Bio, Inc
Tinlarebant is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related...
Belite-Bio-Logo Digital-Full-Color.png
Belite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial Results
March 06, 2024 08:00 ET | Belite Bio, Inc
SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting...
Belite-Bio-Logo Digital-Full-Color.png
Belite Bio to Participate in the Leerink Partners Global Biopharma Conference
March 04, 2024 08:00 ET | Belite Bio, Inc
SAN DIEGO, March 04, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting...
Belite-Bio-Logo Digital-Full-Color.png
Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 07, 2024 08:00 ET | Belite Bio, Inc
SAN DIEGO, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting...
Belite-Bio-Logo Digital-Full-Color.png
Belite Bio to Participate in the Benchmark Company’s Upcoming Discovery One-on-One Investor Conference
November 30, 2023 08:00 ET | Belite Bio, Inc
SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting...
Belite-Bio-Logo Digital-Full-Color.png
Belite Bio to Participate in the BTIG Ophthalmology Day
November 20, 2023 08:00 ET | Belite Bio, Inc
SAN DIEGO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting...
Comparison of the 24-month DDAF lesion growth between Tinlarebant-treated subjects and ProgStar participants
Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial Results
November 13, 2023 20:15 ET | Belite Bio, Inc
Completed enrollment in pivotal Phase 3 “DRAGON” trial for Tinlarebant in adolescent Stargardt disease (“STGD1”) with 104 subjects enrolled across 11 countries worldwideFirst subject dosed with...
Belite-Bio-Logo Digital-Full-Color.png
Belite Bio to Host Webcast on November 14, 2023, to Discuss Third Quarter 2023 Financial Results
November 07, 2023 08:00 ET | Belite Bio, Inc
SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting...
Comparison of the 24-month DDAF lesion growth between Tinlarebant-treated subjects and ProgStar participants
Belite Bio Presents Results from a 24-month, Phase 2 Study of Tinlarebant in Childhood-onset Stargardt Disease at the AAO Annual Meeting
November 06, 2023 08:00 ET | Belite Bio, Inc
Tinlarebant (a/k/a LBS-008) is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced...